Pharmacy Transplant Series: The Basics of Maintenance Immunosuppression

Don't miss Part 2! CLICK HERE for Part 2 of this CE activity ►


This is a product jointly developed by the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)


Pharmacists are often a key part of a successful organ transplant team and incredibly important in improving patient adherence with medications and optimizing overall patient outcomes. Transplant patients are often discharged with 10 or more medications. Many of these patients are faced with complex and changing medication regimens, financial strain and possibly even the lack of a support system. Health-system and specialty pharmacies are in a unique position to improve the transplant patient’s adherence to their medication. Additionally, pharmacists serve as a key resource to other health providers on the transplant team.

The Pharmacy Transplant Series is designed to help pharmacists better understand the very complicated post-transplant immunosuppressive regimens, the basics of immunosuppression and the issues related to infections during the post-transplant period. A particular focus on CMV prophylaxis and treatment regimens will be included.

Learning Objectives

At the completion of this webinar, the participant will be able to:

  • Describe the goals of immunosuppression when managing solid organ transplant patients.
  • Differentiate the various types of drug formulations utilized in maintenance immunosuppression for transplant patients.
  • Explain the mechanisms of action, side effects, and drug interactions that can occur with complicated immunosuppression maintenance regimens.
  • Recognize the role of the specialty pharmacist in improving transplant patients' medication adherence.


Carly D'Agostino, PharmD, BCPS
Clinical Pharmacist, Solid Organ Transplant - Team Lead
Northwestern Memorial Hospital
Chicago, Illinois

Planning Committee

Carly D'Agostino, PharmD, BCPS
Clinical Pharmacist, Solid Organ Transplant - Team Lead
Northwestern Memorial Hospital

Donna B. Filo, RPh
Pharmacy Manager
Amber Pharmacy

Nishita Hira, PharmD, CSP
Clinical Program Manager, Specialty Pharmacy
Cystic Fibrosis/Transplant
AllianceRx Walgreens Prime

Monica V. Mahoney, PharmD, BCPS-AQ ID
Clinical Pharmacy Coordinator - Infectious Diseases
Beth Israel Deaconess Medical Center


Release Date: February 20, 2018
Expiration Date: February 20, 2021


ACPE LogoThis activity is jointly provided by ProCE, Inc., the National Association of Specialty Pharmacy (NASP) and the Society of Infectious Diseases Pharmacists (SIDP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-081-H01-P has been assigned to this home-study knowledge-based activity (initial release date February 20, 2018). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. D’Agostino, Donna Filo and Nishita Hira do not have any relevant commercial and/or financial relationships to disclose. Dr. Mahoney is an Advisory Board member for Cutis Pharma, Melinta Therapeutics, and Roche Pharmaceuticals/Diagnostics; is a Consultant for Group Dynamics in Focus, Krog & Partners, Inc., and Navigant Consulting; and involved in research funded by Forest Pharmaceuticals.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is supported by educational grants from Bristol-Myers Squibb and Shire.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Credit Information

Activity Number Credit Amount Accreditation Period
0221-9999-20-015-H01-P 1 Contact Hour February 20, 2020 - February 20, 2021